VA awards $22.4M for Genomic Sequencing, Foundation Medicine Inc. secures contract

Contract Overview

Contract Amount: $22,374,867 ($22.4M)

Contractor: Foundation Medicine, Inc.

Awarding Agency: Department of Veterans Affairs

Start Date: 2023-10-03

End Date: 2024-10-02

Contract Duration: 365 days

Daily Burn Rate: $61.3K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 7

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: GENOMIC SEQUENCING TESTING SERVICES

Place of Performance

Location: FREDERICKSBURG, SPOTSYLVANIA County, VIRGINIA, 22408

State: Virginia Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $22.4 million to FOUNDATION MEDICINE, INC. for work described as: GENOMIC SEQUENCING TESTING SERVICES Key points: 1. Contract awarded to Foundation Medicine, Inc. for genomic sequencing services. 2. Total contract value is $22.4 million. 3. The contract falls under the Medical Laboratories NAICS code. 4. This award represents a significant investment in advanced diagnostic capabilities for veterans.

Value Assessment

Rating: good

The contract value of $22.4 million for genomic sequencing services appears reasonable given the specialized nature of the work. Benchmarking against similar large-scale genomic testing contracts would provide a more precise assessment, but the price seems competitive for advanced molecular diagnostics.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. This competitive process is expected to drive fair pricing and ensure the government receives the best value for these critical services.

Taxpayer Impact: Taxpayers benefit from a competitive bidding process that aims to secure cost-effective genomic sequencing services for veterans' healthcare.

Public Impact

Enhances diagnostic capabilities for veterans, potentially leading to earlier and more accurate disease detection. Supports personalized medicine initiatives within the VA healthcare system. Provides access to advanced genomic information for treatment planning and research.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Positive Signals

Full and open competition utilized.
Contract awarded for advanced medical services.
Supports veteran healthcare initiatives.

Sector Analysis

The healthcare sector, particularly medical laboratories and diagnostic services, is experiencing rapid technological advancement. Spending in this area is crucial for improving patient outcomes and managing complex diseases. This contract aligns with the VA's commitment to providing cutting-edge healthcare.

Small Business Impact

The data does not indicate any specific provisions or set-asides for small businesses in this contract. Further analysis would be needed to determine if small businesses were involved as subcontractors or if opportunities were missed.

Oversight & Accountability

The Department of Veterans Affairs is responsible for overseeing this contract. Standard procurement regulations and performance monitoring should ensure accountability and adherence to contract terms.

Related Government Programs

Medical Laboratories
Department of Veterans Affairs Contracting
Department of Veterans Affairs Programs

Risk Flags

Potential for data privacy and security concerns.
Need for robust interpretation of complex genomic data.
Ensuring equitable access to advanced diagnostics for all veterans.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $22.4 million to FOUNDATION MEDICINE, INC.. GENOMIC SEQUENCING TESTING SERVICES

Who is the contractor on this award?

The obligated recipient is FOUNDATION MEDICINE, INC..

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $22.4 million.

What is the period of performance?

Start: 2023-10-03. End: 2024-10-02.

What is the expected impact of these genomic sequencing services on veteran health outcomes?

Genomic sequencing can identify genetic predispositions to diseases, guide personalized treatment plans, and improve diagnostic accuracy for various conditions. For veterans, this could lead to more effective therapies, reduced side effects, and better management of chronic or complex illnesses, ultimately enhancing their overall quality of life and healthcare experience.

Are there any potential risks associated with the use of genomic sequencing data by the VA?

Potential risks include data privacy and security breaches, ensuring the ethical use of genetic information, and managing the interpretation of complex genomic data. The VA must implement robust cybersecurity measures and clear ethical guidelines to protect veteran data and ensure responsible application of genomic insights in clinical decision-making.

How does this contract contribute to the VA's overall healthcare effectiveness?

This contract enhances the VA's effectiveness by providing access to advanced diagnostic tools that support precision medicine. It allows for more tailored and potentially more successful treatments, improving patient outcomes and potentially reducing long-term healthcare costs associated with less effective, generalized treatments. It also supports research into veteran-specific health issues.

Industry Classification

NAICS: Health Care and Social Assistance › Medical and Diagnostic Laboratories › Medical Laboratories

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Offers Received: 7

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Roche Holding AG

Address: 150 SECOND STREET, CAMBRIDGE, MA, 02141

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $22,374,867

Exercised Options: $22,374,867

Current Obligation: $22,374,867

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36C10G19D0032

IDV Type: IDC

Timeline